BNET Industries
- Private
- US
Dow Jones Description
Invitrogen is committed to being the leading provider of novel fluorescent reagents and detection solutions that advance scientific and biomedical research worldwide. Supplying superior Molecular Probes products and services, together with striving for customer and employee satisfaction, will be the driving forces of our organization.
Senior Vice President
Ben BulkleyPeer Companies
NAICS Code Biological Product (except Diagnostic) Manufacturing: 325414
News & Analysis
Filter by
invitrogen corp. - All News and Analysis
Invitrogen Corp. Q3 2008 Earnings Conference Call Transcript
Question-and-Answer SessionThank you. [Operator Instructions]. Your first question comes from the line of Tycho Peterson with JP Morgan. Please proceed with your question. Tycho W. Peterson - JP Morgan Hi good afternoon. Wondering maybe, Greg, if you can just comment a little bit more on the VisiGen acquisition, where...
Applied Biosystems Inc. First Quarter Fiscal 2009 Financial Results and Conference Call Scheduled for October 22, 2008
Company Reiterates Outlook for the Quarter NORWALK, Conn. -- Applied Biosystems Inc. (NYSE:ABI) announced today that it will issue fiscal 2009 first quarter financial results on Wednesday, October 22, 2008. Results are scheduled for release before the opening of trading on the New York Stock Exchange. Applied Biosystems...
Invitrogen Joins EPA's Climate Leaders Program
CARLSBAD, Calif. -- As a part of its continued commitment to environmental sustainability, Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced its participation in the U.S. Environmental Protection Agency's (EPA's) Climate Leaders program. By participating in Climate Leaders, Invitrogen has pledged...
Invitrogen Files Merger Notification With European Commission
CARLSBAD, Calif. -- Invitrogen Corporation (NASDAQ:IVGN) today announced that it has filed the necessary formal notification to the European Commission with respect to its pending acquisition of Applied Biosystems Inc. (NYSE:ABI). Under European Commission rules, the Commission has 25 business days following the date of notification to respond to the...
San Diego public stocks
Index Watch Net Index...
Applied Biosystems Announces Internet Availability of Its 2008 Annual Report on Form 10-K
NORWALK, Conn. -- Applied Biosystems Inc. (NYSE: ABI) today announced the Internet availability of its 2008 Annual Report on Form 10-K. The Annual Report on Form 10-K has been filed with the U.S. Securities and Exchange Commission and may be accessed through the Company's investor relations website at http://ir.appliedbiosystems.com. Applied...
Applied Biosystems Sets Date for Special Meeting of Shareholders to Vote on Proposed Merger With Invitrogen Corporation
NORWALK, Conn. -- Applied Biosystems Inc. (NYSE:ABI) today announced it has set the date for a special meeting of its shareholders to consider the proposed merger with Invitrogen Corporation. The special meeting of shareholders will be held on October 16, 2008, at 9:30 a.m. EDT. Applied Biosystems shareholders of record...
All four IBO indexes defy market turbulence
Disappointing economic news continued to weigh on the US markets this month. On July 31, the US reported second-quarter economic growth of 1.9%, compared to economists' expectations of 2.3%. The US also lowered its GDP estimates for the first quarter of this year and the fourth quarter of 2007 to...
Invitrogen Corp. Q2 2008 Earnings Call Transcript
Question-and-Answer Session[Operator Instructions]. And the first question comes from the line of Tycho Peterson from JPMorgan. You may proceed. Tycho W. Peterson - JPMorgan Hi, good morning. Thanks for taking the call. Gregory T. Lucier - Chairman and Chief Executive Officer Good morning. David F. Hoffmeister - Chief Financial...
Half-year litigation review: two trial dates approach
In the first of IBO's twice yearly report on new litigation among analytical instrument and laboratory product providers, we take a look at new patent infringement cases, as well as update the latest developments in other cases. Two cases are scheduled to come to trial in the next few months,...
Decision Makers
| Name (plus bio) | Position |
|---|---|
| Ben Bulkley | Senior Vice President |
| David U'Prichard | Director |
Board of Directors
| Name (plus bio) | Position |
|---|---|
| Donald W Grimm | Board Member |
| Raymond V. Dittamore | Board of Directors |
| W. Ann Reynolds PhD | Board of Directors |
| Organization | Position | Status |
|---|---|---|
| Invitrogen Corporation | Senior Vice President | Current |
| UCSD-CONNECT | Director | Current |
| Organization | Position | Status |
|---|---|---|
| Care Capital, LLC | Venture Partner | Current |
| Red Abbey, LLC | Senior Advisor and Venture Partner | Current |
| University of Glasgow | Honorary Professor | Current |
| Red Abbey, LLC | Advisor | Current |
| Northwestern University | Associate Professor | Current |
| Glasgow University | Honorary Professor | Current |
| Genematrix, Inc. | Board Director | Current |
| Exsar Corporation | Board Director | Current |
| Guilford Pharmaceuticals, Inc. | Director | Current |
| Invitrogen Corporation | Director | Current |
| Cyclacel Limited | Board of Directors | Current |
| GlaxoSmithKline Plc | President | Former |
| SmithKline Beecham Corporation | President of Research and Development | Former |
| Druid Consulting | President | Former |
| Apax Partners Ltd. | Venture Partner | Former |
| Northwestern University School of Medicine | Associate Professor of Pharmacology and Neurobiology | Former |
| Biotechnology Industry Organization | member | Former |
| GlaxoSmithKline Plc | Chairman of Research and Development | Former |
| SmithKline Beecham Corporation | Chairman of R&D | Former |
| Biotechnology Industry Organization | Board Member | Former |
| University of Kansas | Ph.D. in Pharmacology | Former |
| University of Kansas | MS | Former |
| University of Glasgow | B.Sc. in Pharmacology | Former |
| Organization | Position | Status |
|---|---|---|
| Oligoperfect | Founder, Chairman and President, Strategic Design | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Founder, Chairman and President, Strategic Design | Current |
| Resgen Inc. | Founder, Chairman and President, Strategic Design | Current |
| Emiliem, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Hamilton BioVentures | President | Current |
| Molecular Probes | Founder, Chairman and President, Strategic Design | Current |
| Biolayer Corporation Limited | Founder, Chairman and President, Strategic Design | Current |
| Strategic Design | President | Current |
| IDEXX Laboratories, Inc. | Founder, Chairman and President, Strategic Design | Current |
| Seqanswers | Founder, Chairman and President, Strategic Design | Current |
| Microseq | Founder, Chairman and President, Strategic Design | Current |
| Industry Ventures | Founder, Chairman and President, Strategic Design | Current |
| Olink | Founder, Chairman and President, Strategic Design | Current |
| Ionsource, LLC | Founder, Chairman and President, Strategic Design | Current |
| Bioreliance Corporation | Founder, Chairman and President | Current |
| Aegis Therapeutics, LLC | Executive Chairman | Current |
| Strategic Design | Chairman | Current |
| San Diego Regional Chamber of Commerce | Vice Chair | Current |
| Cellzdirect, Inc. | Board of Directors | Current |
| High Throughput Genomics, Inc. | Board of Directors | Current |
| Hamilton BioVentures | Director | Current |
| Intec Telecommunications | Board Member | Current |
| Invitrogen Corporation | Board Member | Current |
| University of Pittsburgh School of Pharmacy | Board Member | Current |
| Angstrom Pharmaceuticals, Inc. | Board of Directors | Current |
| Multiple Peptide Systems Inc | Board of Directors | Current |
| Scripps Clinic | Board Member | Current |
| Hybritech, Inc. | CEO | Former |
| Dura Pharmaceuticals, Inc. | Chief Executive Officer | Former |
| Biosource International, Inc. | Founder, Chairman and President, Strategic Design | Former |
| Hybritech, Inc. | President | Former |
| Copenhagen Capacity | Managing Director | Former |
| Hybritech, Inc. | Director of West Coast Pharmaceutical Sales | Former |
| Eli Lilly and Company | Director of Pharmaceutical Market Research | Former |
| Eli Lilly and Company | management positions | Former |
| U.S. Army | Officer | Former |
| Xcel Pharmaceuticals, Inc. | Former | |
| Verus Pharmaceuticals | Former | |
| Cadence Pharmaceuticals, Inc. | Former | |
| Hybritech, Inc. | Chairman | Former |
| Hybritech | Chairman | Former |
| Biovail Corporation | Chairman | Former |
| Pharmaceutical Market Research | Director | Former |
| Roundtable Inc. | Board of Directors | Former |
| Bioreliance Corporation | Director | Former |
| Somaxon Pharmaceuticals, Inc. | Board of Directors | Former |
| California Healthcare Institute, Inc. | Board of Directors | Former |
| University of Pittsburgh | M.B.A. | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | M.B.A. | Former |
| Baldwin-Wallace College | Master's Degree In Business Administration | Former |
| Pittsburgh Tissue Engineering Initiative, Inc | B.S. In Pharmacy | Former |
| University of Pittsburgh | B.S. In Pharmacy | Former |
Raymond V. Dittamore has served as a Director of the Company since December 2002. Mr. Dittamore is a retired audit partner of Ernst & Young LLP, an international accounting firm. Mr. Dittamore retired in 2001 after 35 years of service with that firm, including 14 years as the managing partner of the firms San Diego office. Mr. Dittamore is also a director of Invitrogen Corporation, Gen-Probe Incorporated, and Digirad Corporation. Mr. Dittamore received a B.S. degree from San Diego State University.
| Organization | Position | Status |
|---|---|---|
| QUALCOMM Incorporated | Board of Directors | Current |
| Molecular Probes | Director | Current |
| Invitrogen Corporation | Board of Directors | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Biolayer Corporation Limited | Director | Current |
| Ionsource, LLC | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Gen-Probe Inc. | Board of Directors | Current |
| Applied Molecular Evolution, Inc. | Director | Current |
| Ernst & Young | partner | Former |
| Ernst & Young | collaborative editor | Former |
| Digirad Corporation | Board of Directors | Former |
| San Diego State University | B.S. | Former |
| QUALCOMM Incorporated | member | Former |
W. Ann Reynolds, 71, formerly President and Professor of Biology at The University of Alabama at Birmingham, located in Birmingham, Alabama, until 2002. Director since 2006; formerly a Director of OCD since 1993. A graduate of Kansas State Teachers College and the University of Iowa, where she earned a Ph.D. degree, Dr. Reynolds previously served as Chancellor of the City University of New York and as Chancellor of the California State University System. In prior years, she was Provost of the Ohio State University and Professor of Anatomy and Vice Chancellor for Research at the University of Illinois at the Medical Center. Dr. Reynolds is a director of Humana, Inc., Abbott Laboratories, Invitrogen Corporation, and the News-Gazette, Champaign, Illinois.
| Organization | Position | Status |
|---|---|---|
| News Gazette Inc. | Director | Current |
| Humana Inc. | Board of Directors | Current |
| Abbott Laboratories | Board of Directors | Current |
| Owens Corning | Board of Directors | Current |
| Industry Ventures | Board of Directors | Current |
| Business-Higher Education Forum | Member of The Board of The Champaign, Urbana News Gazette | Current |
| Olink | Board of Directors | Current |
| KMG America Corporation | Member of The Board of The Champaign, Urbana News Gazette | Current |
| IDEXX Laboratories, Inc. | Board of Directors | Current |
| Resgen Inc. | Board of Directors | Current |
| Maytag Corporation | Board of Directors | Current |
| Ionsource, LLC | Board of Directors | Current |
| Pittsburgh Tissue Engineering Initiative, Inc | Board of Directors | Current |
| Microseq | Board of Directors | Current |
| Abms Member | Board of Directors | Current |
| Invitrogen Corporation | Board of Directors | Current |
| The University of Alabama at Birmingham | President | Former |
| University of Illinois | Professor | Former |
| University of Illinois College of Medicine | Research Professor | Former |
| Emporia State University | M.S. | Former |
| Emporia State University | Bachelors Degree In Biology | Former |
Industry Transcripts by Seeking Alpha
-
Palatin Technologies F1Q10 (Qtr End 9/30/09) Earnings Call Transcript
on Nov 16, 2009about PTN
-
Flamel Technologies SA Q3 2009 Earnings Call Transcript
on Nov 16, 2009about FLML
-
NexMed Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about NEXM
-
InterMune, Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ITMN
-
Arena Pharmaceuticals Inc. Q3 2009 Earnings Call Transcript
on Nov 10, 2009about ARNA
IndustryTop Rated
- How NOT to Write a Biotech Press Release: Just Ask Epeius 5 votes
- Biogen Idec's Social Media Ties Save Tysabri Again; FDA Watching 3 votes
- More Tysabri Problems; Time for a Biogen-Idec Credibility Check 3 votes
- BioCryst's Antiviral Drug Peramivir Aims to Keep Swine-Flu Body Count Low 3 votes
- The 10 Weirdest Drug Stories of the Month 3 votes

